297 related articles for article (PubMed ID: 24524096)
1. Vortioxetine for the treatment of major depression.
Dhir A
Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine for the treatment of major depressive disorder.
Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
[TBL] [Abstract][Full Text] [Related]
3. [Vortioxetine in the treatment of major depression].
de Bartolomeis A; Fagiolini A; Maina G
Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine: first global approval.
Gibb A; Deeks ED
Drugs; 2014 Jan; 74(1):135-45. PubMed ID: 24311349
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of vortioxetine for the treatment of major depressive disorder.
Dhir A; Sarvaiya J
Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
[TBL] [Abstract][Full Text] [Related]
6. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
[TBL] [Abstract][Full Text] [Related]
7. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
8. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
Adell A
IDrugs; 2010 Dec; 13(12):900-10. PubMed ID: 21154150
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
Dubovsky SL
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine hydrobromide, crofelemer, and teduglutide.
Hussar DA; Lye A
J Am Pharm Assoc (2003); 2014; 54(1):91-4. PubMed ID: 24407747
[No Abstract] [Full Text] [Related]
12. [Pharmacological properties of vortioxetine and its pre-clinical consequences].
David DJ; Tritschler L; Guilloux JP; Gardier AM; Sanchez C; Gaillard R
Encephale; 2016 Feb; 42(1 Suppl 1):1S12-23. PubMed ID: 26879252
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
Sanchez C; Asin KE; Artigas F
Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
[TBL] [Abstract][Full Text] [Related]
14. An overview of vortioxetine.
Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
[TBL] [Abstract][Full Text] [Related]
15. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
Dziwota E; Olajossy M
Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
[TBL] [Abstract][Full Text] [Related]
16. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
17. Vortioxetine: A Review in Cognitive Dysfunction in Depression.
Frampton JE
Drugs; 2016 Nov; 76(17):1675-1682. PubMed ID: 27807822
[TBL] [Abstract][Full Text] [Related]
18. [Vortioxetine: a new antidepressant to treat depressive episodes].
Colle R; Corruble E
Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
Berhan A; Barker A
BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]